Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Gonzalez-Angulo

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 2008
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumabF Peintinger, A U Buzdar, H M Kuerer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancersC Mazouni, S-W Kau, D Frye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerC Liedtke, K Broglio, S Moulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2013
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancerM M Kim, P Allen, A M Gonzalez-Angulo, et al.
Oncogene|July 12, 2011
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal fillingC-R Pradeep, W J Köstler, M Lauriola, et al.
Plos One|May 7, 2016
A Set of miRNAs, Their Gene and Protein Targets and Stromal Genes Distinguish Early from Late Onset ER Positive Breast CancerE P Bastos, H Brentani, C A B Pereira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypesH Masuda, T M Brewer, D D Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 2008
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumabF Peintinger, A U Buzdar, H M Kuerer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancersC Mazouni, S-W Kau, D Frye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerC Liedtke, K Broglio, S Moulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2013
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancerM M Kim, P Allen, A M Gonzalez-Angulo, et al.
Oncogene|July 12, 2011
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal fillingC-R Pradeep, W J Köstler, M Lauriola, et al.
Plos One|May 7, 2016
A Set of miRNAs, Their Gene and Protein Targets and Stromal Genes Distinguish Early from Late Onset ER Positive Breast CancerE P Bastos, H Brentani, C A B Pereira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypesH Masuda, T M Brewer, D D Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Pageof 3